According to CoinMeta, ShengNuo Biology announced that its wholly-owned subsidiaries Meishan HuiLong and ShengNuo Pharmaceutical have recently received the "Drug Export Sales Certificate of the People's Republic of China" issued by the Sichuan Provincial Drug Administration. The product name for both is Telbopide (tirzepatide), and the dosage form is active pharmaceutical ingredient (API). The validity periods of the certificates are October 19, 2029, and November 11, 2029, respectively. At the same time, ShengNuo Pharmaceutical has obtained the certification document for the export of Telbopide API to the European Union, which proves that its Telbopide API meets the requirements of Chinese drug regulations (GMP), and is equivalent to the requirements of the European Union, the World Health Organization, and the drug regulations of ICH Q7 (GMP).